Roswell Park Breast Surgery Chief Gives Keynote Talk on Immunotherapy for Breast Cancer

Address to Japan Society of Clinical Oncology focuses
on opportunities to expand benefits to more patients

  • Accomplished surgeon-scientist joined Roswell Park in 2016
  • Currently, immunotherapies work well for very few patients with breast cancer
  • Dr. Takabe also speaking on how to support development of oncology leaders
     
kazuaki_takabe_-_surgical_suite_october_18_2019_18_2.jpg

Dr. Kazuaki Takabe, Roswell Park’s Chief of Breast Surgery, gave the keynote address at the annual meeting of the Japan Society of Clinical Oncology.

BUFFALO, N.Y. — Roswell Park Comprehensive Cancer Center’s Chief of Breast Surgery, Kazuaki Takabe, MD, PhD, FACS, gave an Oct. 24 keynote address on immunotherapy for breast cancer at the 57th Annual Meeting of the Japan Society of Clinical Oncology (JSCO).

“Immunotherapy is becoming another major tool to fight many cancers, but breast cancer has been behind on this because it’s a cancer where we see very little lymphocyte infiltration, which is a major factor in whether these treatments will be effective,” notes Dr. Takabe, a surgeon-scientist who is also The Alfiero Foundation Endowed Chair in Breast Oncology and Professor of Oncology at the Buffalo, N.Y.-based cancer center. “Currently, immunotherapies for breast cancer are effective in only about 3% of patients. But we have a lot of opportunity to apply what we know toward making immunotherapy work for a much larger share of patients with the disease.”

Dr. Takabe joined Roswell Park’s faculty in 2016. His background includes training in general surgery both at the University of California, San Diego, and in Japan; specialized training in surgical oncology and service as an attending surgical oncologist and faculty member at the Medical College of Virginia Hospital, Virginia Commonwealth University School of Medicine; and postdoctoral training at the Salk Institute in La Jolla, California. 

On Friday, Oct. 25, Dr. Takabe also led a discussion on the roles of Japanese oncologists in global oncology and how JSCO’s U.S. counterpart, the American Society of Clinical Oncology, is addressing the challenge of developing future leaders.

The meeting, the theme of which is “Tackling the Needs of Society and Medicine,” continues through Oct. 26 at the Fukuoka International Congress Center in Fukuoka, Japan.

###


Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@RoswellPark.org.

Roswell Park Breast Surgery Chief Gives Keynote Talk on Immunotherapy for Breast Cancer

Roswell Park Breast Surgery Chief Gives Keynote Talk on Immunotherapy for Breast Cancer

Roswell Park

4 weeks
8 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Up Next Autoplay
Treatment-Free Survival, With and Without Toxicity
Treatment-Free Survival, With and Without Toxicity
Category: Kidney Cancer
0 Views
kidneycancer 36 minutes
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Category: Kidney Cancer
0 Views
kidneycancer 51 minutes
What's To Come in Modern Imaging Technology
What's To Come in Modern Imaging Technology
Category: Kidney Cancer
1 Views
kidneycancer 20 hours
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Category: Acute Myelogenous Leukemia
4 Views
Cancer-News 23 hours
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
Category: Breast Cancer
6 Views
Cancer-News 1 day
Modern Imaging Technology
Modern Imaging Technology
Category: Kidney Cancer
3 Views
kidneycancer 1 day
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
Category: News
2 Views
Cancer-News 1 day
Management of Clinical Cases in Kidney Cancer
Management of Clinical Cases in Kidney Cancer
Category: Kidney Cancer
4 Views
kidneycancer 2 days
Kidney Cancer Program & SPORE
Kidney Cancer Program & SPORE
Category: Kidney Cancer
1 Views
kidneycancer 2 days
Researchers Find Common Measures of Immune Status, Inflammation Can Predict Mortality
Researchers Find Common Measures of Immune Status, Inflammation Can Predict Mortality
Category: News
4 Views
Cleveland Clinic 2 days